Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Azenosertib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zentalis Shares Azenosertib Data in TNBC at AACR 2026
    Zentalis Shares Azenosertib Data in TNBC at AACR 2026

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187979

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    Zentalis Presents Azenosertib Data in Triple-Negative Cancer
    Zentalis Presents Azenosertib Data in Triple-Negative Cancer

    17 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/17/3276461/0/en/Zentalis-Pharmaceuticals-To-Present-Azenosertib-Preclinical-Data-in-Triple-Negative-Breast-Cancer-and-Real-World-Analysis-of-Unmet-Need-in-Cyclin-E1-Positive-Ovarian-Cancer-at-AACR.html

    GLOBENEWSWIRE
    17 Apr 2026
    Share Share
    Zentalis sets 400mg azenosertib dose for pivotal ovarian study
    Zentalis sets 400mg azenosertib dose for pivotal ovarian study

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270889/0/en/Zentalis-Pharmaceuticals-Announces-400mg-QD-5-2-Azenosertib-Monotherapy-as-the-Pivotal-Study-Dose-in-Cyclin-E1-Positive-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share
    Zentalis Pharma To Showcase Two Posters At (AACR) Annual Meeting
    Zentalis Pharma To Showcase Two Posters At (AACR) Annual Meeting

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257674/0/en/Zentalis-Pharmaceuticals-to-Present-Two-Posters-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2026.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Zentalis Pharma Joins Investor Conferences
    Zentalis Pharma Joins Investor Conferences

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240158/0/en/Zentalis-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share
    Zentalis Pharma Joins Upcoming Investor Conference
    Zentalis Pharma Joins Upcoming Investor Conference

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3231602/0/en/Zentalis-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conference.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.